Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fresenius Kabi Glucagon vs GlucaGen
NCT02086227Phase 1Completed
- Sponsor
- Fresenius Kabi
- Start
- May 2013
- Primary completion
- Jun 2013
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of glucagon in hypoglycemia (2 arms), sponsored by Fresenius Kabi. Primary endpoints: Plasma Glucagon Concentration at 4 hours and Plasma Glucose Concentration at 4 hours. Started May 2013; status: completed.
02
Drugs
glucagon
03
Conditions
hypoglycemia
Beyond the preview
Go deeper on NCT02086227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02086227.